Enhancing Anti-Tumoral Potential of CD-NHF by Modulating PI3K/Akt Axis in U87 Ex Vivo Glioma Model
Open Access
- 8 April 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (8) , 3873
Abstract
Background: In the latest years, there has been an increased interest in nanomaterials that may provide promising novel approaches to disease diagnostics and therapeutics. Our previous results demonstrated that Carbon-dots prepared from N-hydroxyphthalimide (CD-NHF) exhibited anti-tumoral activity on several cancer cell lines such as MDA-MB-231, A375, A549, and RPMI8226, while U87 glioma tumor cells were unaffected. Gliomas represent one of the most common types of human primary brain tumors and are responsible for the majority of deaths. In the present in vitro study, we expand our previous investigation on CD-NHF in the U87 cell line by adding different drug combinations. Methods: Cell viability, migration, invasion, and immunofluorescent staining of key molecular pathways have been assessed after various treatments with CD-NHF and/or K252A and AKTVIII inhibitors in the U87 cell line. Results: Association of an inhibitor strongly potentiates the anti-tumoral properties of CD-NHF identified by significant impairment of migration, invasion, and expression levels of phosphorylated Akt, p70S6Kinase, or by decreasing expression levels of Bcl-2, IL-6, STAT3, and Slug. Conclusions: Using simultaneously reduced doses of both CD-NHF and an inhibitor in order to reduce side effects, the viability and invasiveness of U87 glioma cells were significantly impaired.Keywords
Funding Information
- Romanian National Authority for Scientific Research - UEFISCDI (PN-III-P1-1.2-PCCDI-2017-0083 (project number 37PCCDI/2018))
This publication has 46 references indexed in Scilit:
- Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastomaAnnals of Oncology, 2017
- Brain metastasis: Unique challenges and open opportunitiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2017
- Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal TransitionCell Reports, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistanceNature, 2015
- GliomaNature Reviews Disease Primers, 2015
- EMT-activating transcription factors in cancer: beyond EMT and tumor invasivenessCellular and Molecular Life Sciences, 2012
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Glioblastoma multiforme: a review of where we have been and where we are goingExpert Opinion on Investigational Drugs, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005